News from vivus, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 10, 2010, 08:00 ET

VIVUS to Present at Four Upcoming Investor Conferences

VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the...

Aug 25, 2010, 08:00 ET

Data on VIVUS' Qnexa® to Be Presented at the European Society of Cardiology Congress

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be featured in two poster...

Aug 05, 2010, 08:00 ET

VIVUS to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference

VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Bank of...

Aug 03, 2010, 07:00 ET

Data on VIVUS' Qnexa® to be Presented at AADE Annual Meeting

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be featured in two poster...

Aug 02, 2010, 16:00 ET

VIVUS Reports Second Quarter and First Six Months 2010 Financial Results

VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today...

Jul 29, 2010, 07:15 ET

Data on VIVUS' Qnexa® To Be Presented at the National Medical Association Annual Assembly

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the  2010...

Jul 15, 2010, 17:40 ET

VIVUS Comments on FDA Advisory Committee Panel Meeting on QNEXA® (phentermine/topiramate) Controlled Release Capsules for the Treatment of Obesity

VIVUS, Inc. (Nasdaq: VVUS) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration...

Jul 12, 2010, 07:00 ET

Data on VIVUS' Qnexa to be Presented at International Congress on Obesity

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the 11th International...

Jun 22, 2010, 07:00 ET

Six Presentations at the ADA Annual Meeting will Highlight Data on VIVUS' Qnexa

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be featured in a total of six...

Jun 16, 2010, 07:00 ET

Endocrine Society's Annual Meeting to Feature Data on VIVUS' Qnexa

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the Endocrine...

Jun 08, 2010, 07:00 ET

Positive Results From Phase 2 Study of Qnexa in Obstructive Sleep Apnea Presented at Sleep Meeting

VIVUS, Inc. (Nasdaq: VVUS) today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the...

Jun 07, 2010, 07:00 ET

VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Diabetics With Erectile Dysfunction

VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of...

Jun 04, 2010, 08:00 ET

VIVUS to Present at Three Upcoming Investor Conferences

VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at three investment conferences during the...

Jun 01, 2010, 18:25 ET

Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction Presented at AUA Annual Meeting

VIVUS, Inc. (Nasdaq: VVUS) today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and...

May 28, 2010, 07:00 ET

Phase 3 Data on VIVUS' Avanafil for Erectile Dysfunction to be Featured at the AUA 2010 Annual Meeting

VIVUS, Inc. (Nasdaq: VVUS) today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 (PDE5) inhibitor therapy...

May 13, 2010, 07:00 ET

Data on VIVUS' Qnexa to be Featured at World Congress Highlighting Metabolic Disease and Related Disorders

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the 3rd World Congress...

May 10, 2010, 08:00 ET

VIVUS To Present at Four Upcoming Investor Conferences

VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the...

May 05, 2010, 08:00 ET

Data on VIVUS' Qnexa to be Presented at European Congress Focused on Cardiovascular Prevention and Rehabilitation

VIVUS, Inc. (Nasdaq: VVUS) today announced that new data on Qnexa®, an investigational drug candidate, will be presented at EuroPRevent 2010,...

May 04, 2010, 18:52 ET

VIVUS Grants Stock Option to New Senior Vice President and Chief Commercial Officer

VIVUS, Inc. (Nasdaq: VVUS) today announced that, in accordance with NASDAQ Listing Rule 5635, Michael P. Miller, the Company's new senior vice...

May 03, 2010, 16:01 ET

VIVUS Reports First Quarter 2010 Financial Results

VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today...